Preferred Label : venetoclax;
Obsolete resource : false;
MeSH note : a BCL-2 inhibitor with antineoplastic activity; structure in first source;
MeSH synonym : 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-;
MeSH hyponym : RG7601;
Is substance : O;
UNII : N54AIC43PW;
Origin ID : C579720;
UMLS CUI : C4079830;
ATC code(s)
CISMeF manual mappings
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/venclyxto-10-mg-50mg-100-mg-comprimes-pellicules?#
2025
false
false
false
France
French
venetoclax
venetoclax
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
leukemia, myeloid, acute
precursor cell lymphoblastic Leukemia-Lymphoma
Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
leukemia, lymphocytic, chronic, B-Cell
drug information
Product containing only venetoclax in oral dose form (medicinal product form)
guidelines for drug use
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://ansm.sante.fr/tableau-marr/venetoclax
2024
false
false
false
France
French
risk management
venetoclax
venetoclax
patient education handout
tumor lysis syndrome
administration, oral
antineoplastic agents
---
https://www.has-sante.fr/jcms/p_3448141/fr/venclyxto-venetoclax-leucemie-lymphoide-chronique
2023
France
evaluation of the transparency committee
venetoclax
venetoclax
leukaemia
leukemia, lymphoid
Chronic lymphocytic leukemia
chronic lymphocytic leukemia
leukemia, lymphocytic, chronic, B-Cell
---
https://www.has-sante.fr/jcms/p_3351236/fr/venclyxto-venetoclax-leucemie-lymphoide-chronique
2022
false
false
false
France
Obinutuzumab/Venetoclax Regimen
evaluation of the transparency committee
venetoclax
chronic lymphocytic leukemia
leukemia, lymphoid
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
leukaemia
venetoclax
---
https://www.has-sante.fr/jcms/p_3367900/fr/venclyxto-venetoclax-llc-en-association-avec-l-obinutuzumab
2022
France
evaluation of the transparency committee
venetoclax
obinutuzumab
association
venetoclax
obinutuzumab
leukemia, lymphocytic, chronic, B-Cell
---
https://ansm.sante.fr/informations-de-securite/venclyxto-r-v-venetoclax-comprimes-pellicules-recommandations-actualisees-concernant-le-syndrome-de-lyse-tumorale-slt-chez-les-patients-atteints-de-leucemie-lymphoide-chronique
2021
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
venetoclax
tumor lysis syndrome
leukemia, lymphocytic, chronic, B-Cell
venetoclax
antineoplastic agents
administration, oral
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://www.has-sante.fr/jcms/p_3284614/fr/venclyxto-venetoclax-leucemie-aigue-myeloide
2021
false
false
false
France
evaluation of the transparency committee
venetoclax
sulfonamides
treatment outcome
insurance, health, reimbursement
administration, oral
venetoclax
leukemia, myeloid, acute
antineoplastic agents
adult
antineoplastic combined chemotherapy protocols
azacitidine
Bridged Bicyclo Compounds, Heterocyclic
---
https://www.has-sante.fr/jcms/p_3106158/fr/venclyxto
2020
false
false
false
France
venetoclax
drug therapy, combination
Rituximab
adult
leukemia, lymphocytic, chronic, B-Cell
administration, oral
antineoplastic agents
venetoclax
evaluation of the transparency committee
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://www.ansm.sante.fr/actualites/venclyxto-venetoclax-signal-de-securite-issu-de-lessai-clinique-evaluant-le-venetoclax-dans-le-traitement-du-myelome-multiple
2019
false
false
false
France
French
pharmacovigilance note
clinical trials as topic
multiple myeloma
Infections
Infections
venetoclax
antineoplastic agents
venetoclax
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://www.has-sante.fr/jcms/p_3106167/fr/venclyxto
2019
false
false
false
France
French
evaluation of the transparency committee
venetoclax
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00339
2018
false
false
false
Canada
French
English
drug information
venetoclax
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://www.has-sante.fr/portail/jcms/c_2788624/fr/venclyxto
https://www.has-sante.fr/portail/jcms/c_2788624/fr/venclyxto-venetoclax-inhibiteur-de-bcl-2
2017
false
false
false
France
French
treatment outcome
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
administration, oral
B-Cell leukemia 2 family proteins
antineoplastic agents
antineoplastic agents
leukemia, lymphocytic, chronic, B-Cell
Loss of Chromosome 17p
genes, p53
mutation
adult
aged
venetoclax
evaluation of the transparency committee
venetoclax
venetoclax
Proto-Oncogene proteins c-bcl-2
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://www.ema.europa.eu/medicines/human/EPAR/Venclyxto
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
venetoclax
venetoclax
leukemia, lymphocytic, chronic, B-Cell
drug approval
europe
risk assessment
pregnancy
breast feeding
drug interactions
administration, oral
B-Cell leukemia 2 family proteins
antineoplastic agents
antineoplastic agents
leukemia, lymphocytic, chronic, B-Cell
Loss of Chromosome 17p
genes, p53
product surveillance, postmarketing
mutation
continuity of patient care
drug monitoring
adult
aged
drug evaluation, preclinical
Response Rate
venetoclax
venetoclax
venetoclax
Proto-Oncogene proteins c-bcl-2
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
---
https://ansm.sante.fr/tableau-atu-rtu/venetoclax-abbvie-10-mg-50-mg-et-100-mg-comprimes-pellicules
2016
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
adult
leukemia, lymphocytic, chronic, B-Cell
chromosome 17 deletion
mutation
TP53 Gene
venetoclax
administration, oral
antineoplastic agents
drug evaluation, preclinical
treatment outcome
Proto-Oncogene proteins c-bcl-2
venetoclax
venetoclax
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
Smith-Magenis syndrome
chromosome deletion
chromosomes, human, pair 17
---